Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

320
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
320
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

159
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
159
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

119
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
119

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

Clinical pharmacology and therapeutics·2026
Same author

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

CPT: pharmacometrics & systems pharmacology·2026
Same author

The Future of Clinical Translational Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
查看所有相关文章

相关实验视频

Updated: May 26, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.1K

关于有条件模拟与瘤大小整体生存模型的教程,以支持瘤学药物开发.

Sebastiaan C Goulooze1, Morris Muliaditan1, Richard C Franzese2

  • 1LAP&P Consultants, Leiden, the Netherlands.

CPT: pharmacometrics & systems pharmacology
|February 22, 2025
PubMed
概括
此摘要是机器生成的。

本教程解释了瘤大小 (TS) -整体存活率 (OS) 模型和条件模拟如何使用早期疗效数据支持瘤药物开发决策. 这些方法可以从中期研究结果中预测长期结果.

关键词:
方法论 方法论 方法论基于模型的药物开发.瘤学 在瘤学方面.人口的药学动力学.模拟模拟是指一个模拟模拟.替代终点是一个替代终点.生存分析,生存分析.这些都是瘤,瘤.

更多相关视频

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204

相关实验视频

Last Updated: May 26, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.1K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

204

科学领域:

  • 在瘤学瘤学.
  • 生物统计学 生物统计学
  • 药物开发 药物开发

背景情况:

  • 整体存活率 (OS) 是瘤药物批准的黄金标准,但初始数据往往有限.
  • 早期药物开发决策依赖于替代终点,如客观反应率和无进展生存率.
  • 在临床试验的早期收集的瘤大小 (TS) 数据可以用来预测长期的生存状况.

研究的目的:

  • 为使用瘤大小-总生存率 (TS-OS) 模型与条件模拟用于瘤药物开发提供全面的教程.
  • 通过早期疗效和TS数据预测长期的OS来证明如何支持决策.
  • 引导研究人员选择,应用和解释正在进行的研究的TS-OS模型和模拟.

主要方法:

  • 利用治疗不可知的TS-OS链接功能,将早期瘤大小测量与预测的OS连接起来.
  • 将条件模拟 (贝叶斯预测) 应用到正在进行的研究中,使用临时的TS和OS数据.
  • 详细说明模型选择,数据应用,模拟执行,输出生成和解释的步骤.

主要成果:

  • 基于早期的疗效读数,TS-OS模型提供了一个框架来预测潜在的后期成功.
  • 条件模拟提供了一种方法来估计正在进行的瘤学试验的长期OS结果.
  • 该教程概述了在药物开发中实施这些先进的统计方法的实际步骤.

结论:

  • 使用TS-OS模型进行有条件模拟可以提高瘤药物开发中的知情决策.
  • 通过这些模型利用早期的TS和OS数据可以优化资源配置和试验策略.
  • 对模拟输出的准确解释和沟通对于有效的决策支持至关重要.